Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients with B-ALL. Chemotherapy during the first month causes large gains in body fat in most people, even those who start chemotherapy at a healthy weight. This study is being done to find out if caloric restriction achieved by a personalized nutritional menu and exercise plan during routine chemotherapy can make the patient's ALL more sensitive to chemotherapy and also reduce the amount of body fat gained during treatment. The goals of this study are to help make chemotherapy more effective in treating the patient's leukemia as demonstrated by fewer patients with leukemia minimal residual disease (MRD) while also trying to reduce the amount of body fat that chemotherapy causes the patient to gain in the first month.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek od 7 do 25 lat
- •Nowo rozpoznana białaczka z komórek B typu ALL
- •Pierwsza linia leczenia białaczki ALL
- •Leczenie zawierające standardowe chemioterapeutyki (vincristyna, kortykosteroidy, pegaspargaza, daunorubicyna lub doksyrubicyna)
- •Planowany czas indukcji poniżej 35 dni
- •Prawidłowa funkcja organów wymagana do rozpoczęcia chemioterapii
- •Zadowalający stan zdrowia (wynik Karnofsky'ego lub Lansky'ego powyżej 50%)
- •Test ciążowy negatywny (dla dziewczyn w wieku rozrodczym)
✗ Disqualifies
- •Niedowaga w momencie włączenia do badania
- •Zespół Downa lub wrodzona skłonność do uszkodzenia DNA
- •Wcześniejsze leczenie nowotworu
- •Ciąża
- •Poważne zaburzenia w spożywaniu pokarmów wymagające stosowania sztucznego żywienia
- •Niemożność uczestniczenia w programie (na przykład poważne opóźnienie w rozwoju)
- •Stosowanie terapii przeciwko CD20 podczas indukcji
Simplified criteria — AI translation
Trial details
- Minimum age
- 7 Years
- Maximum age
- 25 Years
- Last updated (source)
- August 19, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (16)
Children's Hospital Los Angeles
Los Angeles, United States
Children's Hospital Orange County
Orange, United States
UCSF School of Medicine
San Francisco, United States
Colorado Children's Hospital
Denver, United States
Children's Healthcare of Atlanta at Egleston
Atlanta, United States
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, United States
Children's Mercy Hospital
Kansas City, United States
C.S. Mott University of Michigan
Ann Arbor, United States
Children's Hospitals and Clinics of Minnesota
Minneapolis, United States
Levine Children's Hospital
Charlotte, United States
Cincinnati Children's Hospital Medical Center
Cincinnati, United States
Oregon Health & Science University
Portland, United States
Children's Hospital of Philadelphia
Philadelphia, United States
University of Texas, Southwestern
Dallas, United States
Baylor Texas Children's Hospital
Houston, United States
Primary Children's Hospital
Salt Lake City, United States
Trial contact
Ellynore Florendo
Suganya Rajendran
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/20/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.